<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994561</url>
  </required_header>
  <id_info>
    <org_study_id>VIA-004</org_study_id>
    <nct_id>NCT04994561</nct_id>
  </id_info>
  <brief_title>VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements</brief_title>
  <official_title>Pilot Study to Test the Safety and Efficacy of Metformin, Dasatinib, Rapamycin and Nutritional Supplements (Bio-quercetin; Bio-fisetin; Glucosamine; Nicotinamide Riboside; Trans-resveratrol) in Reducing Clinical Measures of Aging in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitality in Aging Research Group, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitality in Aging Research Group, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the safety and efficacy of study drugs and supplements on clinical&#xD;
      (structural and functional) signs of aging and to explore/identify other possible biological&#xD;
      measures of aging.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>through study completion, up to post treatment phone (approx. Day 532)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visceral adipose tissue fat tissue (volume (in^3)) physiological parameter value measured by DEXA scan</measure>
    <time_frame>Change from baseline to Visit 20 (approx. Day 502)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic blood pressure physiological parameter value measured with a blood pressure cuff</measure>
    <time_frame>Change from baseline to Visit 20 (approx. Day 502)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Senescent cell-cycle arrest physiological parameter value measured by MMP-9 laboratory test</measure>
    <time_frame>Change from baseline to Visit 20 (approx. Day 502)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose control (insulin resistance) physiological parameter as measured by HOMA-IR (mg/dL) calculation value</measure>
    <time_frame>Change from baseline to Visit 20 (approx. Day 502)</time_frame>
    <description>insulin and glucose laboratory values are collected to computer the measurement used</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DNA Methylation physiological parameter as measured by 2019 GrimAge Clock laboratory test</measure>
    <time_frame>Change from baseline to Visit 20 (approx. Day 502)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Subjects receiving study drugs and nutritional supplements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible and consented subjects will receive study drugs and nutritional supplements as described in the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Drugs and Nutritional Supplements</intervention_name>
    <description>Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.&#xD;
Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.&#xD;
Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.&#xD;
Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.&#xD;
Once subject is taking rapamycin, they will continue on this intervention for 12 months.</description>
    <arm_group_label>Subjects receiving study drugs and nutritional supplements</arm_group_label>
    <other_name>metformin, dasatinib, rapamycin and nutritional supplements (bio-quercetin; bio-fisetin; glucosamine; nicotinamide riboside; trans-resveratrol)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects 65 years of age or older&#xD;
&#xD;
          2. Received full dose of COVID-19 vaccine&#xD;
&#xD;
          3. Fasting Glucose: &gt; 60 - &lt; 125 mg/dl;&#xD;
&#xD;
          4. HbA1C: &lt;/= 6.4&#xD;
&#xD;
          5. Vitamin D: &gt; 30 ng/mL&#xD;
&#xD;
          6. Homocysteine &lt; 14 mol/L&#xD;
&#xD;
          7. B12 levels &gt;232 pg/mL&#xD;
&#xD;
          8. Ferritin: &gt; 30 ng/mL&#xD;
&#xD;
          9. Cystatin C: &gt; 0.62 mg/L&#xD;
&#xD;
         10. eGFR &gt; 45 mL/min/1.73 m2&#xD;
&#xD;
         11. BMI &gt; 18 kg/m2 &lt; 35 kg/m²&#xD;
&#xD;
         12. Stable body weight (+/-10 lbs.) over last 6 months&#xD;
&#xD;
         13. Be willing to travel to the study facility as required for this study&#xD;
&#xD;
         14. Be willing to avoid taking antacids 2 hours prior and 2 hours after taking dasatinib&#xD;
&#xD;
         15. Be willing to discontinue proton pump inhibitors&#xD;
&#xD;
         16. Be willing to discontinue St. John's Wort&#xD;
&#xD;
         17. Be willing to discontinue medication/supplements, if applicable, for a washout period&#xD;
             and while participating on this study.&#xD;
&#xD;
         18. If taking metformin for anti-aging, willing to washout for 2 months prior to&#xD;
             initiating protocol intervention.&#xD;
&#xD;
         19. Be willing to take the investigational product(s) according to schedule and keep a&#xD;
             diary for compliance monitoring.&#xD;
&#xD;
         20. Has not participated in another clinical trial within last 30 days&#xD;
&#xD;
         21. If applicable, five years or more post cancer treatment and disease free (define as&#xD;
             tumor free or 5 years of clean PET/CT scans).&#xD;
&#xD;
         22. Able to provide signed written informed consent prior to any study specific procedures&#xD;
             being performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide written informed consent.&#xD;
&#xD;
          2. ECOG score &gt;/= 2&#xD;
&#xD;
          3. More than 1 alcoholic drinks consumed per day.&#xD;
&#xD;
          4. Anemic (defined as hemoglobin (Hb) levels &lt; 12.0 g/dL in women and &lt; 13.0 g/dL in men)&#xD;
&#xD;
          5. Thrombocytopenia (defined as platelet count &lt; 100 × 10^9/L&#xD;
&#xD;
          6. Neutropenia (defined as &lt; 1.0-1.5 × 10^9 neutrophils/L (mild))&#xD;
&#xD;
          7. Any allergy to any medications or supplements used on this trial.&#xD;
&#xD;
          8. Shellfish or iodine allergy (note: glucosamine sulfate supplement contains shellfish&#xD;
             (shrimp, crab)&#xD;
&#xD;
          9. Clinically significant vital signs (e.g. uncontrolled hypertension &gt;/= 180/100) or lab&#xD;
             abnormalities (defined as platelet count &lt; 100 × 10^9/L; absolute granulocyte count &lt;&#xD;
             1,000/mm3; ALT (SGOT) &gt; 2.0 times the upper limit of normal range; total bilirubin &gt;&#xD;
             2.5 times the upper limit of normal range) at baseline&#xD;
&#xD;
         10. HIV and/or Hepatitis infection&#xD;
&#xD;
         11. Immunosuppressed due to any condition (e.g. transplant).&#xD;
&#xD;
         12. Taking concurrent medications that may interfere with the drugs or supplements used on&#xD;
             this study.&#xD;
&#xD;
         13. Any concurrent uncontrolled medical condition or psychiatric illness which could place&#xD;
             the patient at unacceptable risk of study treatment.&#xD;
&#xD;
         14. Other concerns that in the PI's judgment will be a potential safety issue for the&#xD;
             subject or that precludes the ability to provide informed consent or complete the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Anne Weinstock</last_name>
    <role>Study Director</role>
    <affiliation>Vitality in Aging</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Anne Weinstock</last_name>
    <phone>561-245-7877</phone>
    <email>eaweinstock@VitalityInAging.org</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Cell senescence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

